Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an update.
Prescient Therapeutics Limited has announced the quotation of 171,732,250 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of August 4, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could positively impact its operations and stakeholder interests.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a company operating in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is primarily engaged in advancing targeted and personalized medicine approaches to improve treatment outcomes for cancer patients.
Average Trading Volume: 1,134,714
Technical Sentiment Signal: Hold
Current Market Cap: A$37.04M
See more data about PTX stock on TipRanks’ Stock Analysis page.